Mcs/Mφs are required for regeneration of muscle function following ischemic injury. (A) Timeline showing clodronate treatment, injury, and injection to the ischemic TA. (B) Quantification of CD45+ cells in the TA, day 9, flow cytometry data. (C) Gating of CD45+ cells. (D–F) Number of Mφs (CD11c−/CD11b+/Ly6G−/Ly6C−/F4/80+) (D), Mcs (CD11c−/CD11b+/Ly6G−/Ly6C+/F4/80−) (E), and Mcs/Mφs (CD11c−/CD11b+/Ly6G−/Ly6C+/F4/80+) (F) in the TA. (G and H) Maximum TA contraction force and velocity of three tests. Force was normalized to TA mass. Data are means ± SEM, n = 7. *P < 0.05; ***P < 0.001; NS, not significant. Clod, clodronate; Cont, contralateral; Isch, ischemic.